Wall Street analysts predict that BioLife Solutions Inc (NASDAQ:BLFS) will announce $5.29 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for BioLife Solutions’ earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $5.61 million. BioLife Solutions reported sales of $2.96 million during the same quarter last year, which would suggest a positive year over year growth rate of 78.7%. The company is expected to announce its next earnings results on Thursday, November 8th.

According to Zacks, analysts expect that BioLife Solutions will report full-year sales of $19.88 million for the current financial year, with estimates ranging from $19.10 million to $20.66 million. For the next financial year, analysts anticipate that the firm will post sales of $28.66 million per share, with estimates ranging from $26.00 million to $30.22 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow BioLife Solutions.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 9th. The medical equipment provider reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. The business had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $5.20 million. BioLife Solutions had a net margin of 1.76% and a return on equity of 2.24%.

A number of brokerages have recently commented on BLFS. BidaskClub cut shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 7th. B. Riley began coverage on shares of BioLife Solutions in a research note on Thursday, June 7th. They set a “buy” rating and a $14.00 price objective on the stock. Northland Securities reaffirmed a “buy” rating and set a $18.00 price objective on shares of BioLife Solutions in a research note on Friday, August 10th. Maxim Group reaffirmed a “buy” rating and set a $26.00 price objective on shares of BioLife Solutions in a research note on Wednesday, September 5th. Finally, TheStreet raised shares of BioLife Solutions from a “d” rating to a “c-” rating in a research note on Tuesday, September 11th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $22.33.

Shares of NASDAQ BLFS traded down $0.41 during midday trading on Monday, reaching $18.11. 311,600 shares of the stock were exchanged, compared to its average volume of 209,404. The stock has a market capitalization of $314.09 million, a price-to-earnings ratio of -86.67 and a beta of 1.46. BioLife Solutions has a twelve month low of $4.63 and a twelve month high of $26.35.

In related news, Director Joseph C. Schick sold 4,765 shares of the business’s stock in a transaction dated Friday, August 24th. The shares were sold at an average price of $25.96, for a total value of $123,699.40. Following the sale, the director now directly owns 10,000 shares in the company, valued at approximately $259,600. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael Rice sold 12,540 shares of the business’s stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $21.55, for a total transaction of $270,237.00. Following the completion of the sale, the chief executive officer now owns 152,057 shares in the company, valued at $3,276,828.35. The disclosure for this sale can be found here. Insiders have sold a total of 582,385 shares of company stock worth $7,397,812 in the last ninety days. Corporate insiders own 38.50% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Casdin Capital LLC purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $11,410,000. Jane Street Group LLC purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $173,000. Granahan Investment Management Inc. MA purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $1,361,000. Sandler Capital Management purchased a new stake in BioLife Solutions in the 2nd quarter valued at about $1,723,000. Finally, Manatuck Hill Partners LLC raised its holdings in BioLife Solutions by 28.4% in the 2nd quarter. Manatuck Hill Partners LLC now owns 64,200 shares of the medical equipment provider’s stock valued at $733,000 after buying an additional 14,200 shares during the period. Hedge funds and other institutional investors own 27.77% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets patented tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced, and delayed-onset cell damage and death.

Read More: Technical Analysis of Stocks and What It Means

Get a free copy of the Zacks research report on BioLife Solutions (BLFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.